Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GD2 expression in breast cancer.

Giulia Orsi1, Monica Barbolini1, Guido Ficarra2,3

  • 1Department of Medical and Surgical Sciences for Children and Adults, University-Hospital of Modena and Reggio Emilia, 71-41124 Modena, Italy.

Oncotarget
|April 19, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026
Same author

Evolution of ER-cut-off definition in clinical trials for triple negative breast cancer: trends and patterns over 15 years.

Breast (Edinburgh, Scotland)·2026
Same author

Clinical implications and biomarkers in the PACT-21 CASSANDRA trial - Authors' reply.

Lancet (London, England)·2026
Same author

Preparing real-world data through common data model harmonization of cancer patient records in the COMNet platform at the Modena Oncology Center.

Frontiers in digital health·2026
Same author

Management of Patients with Suspected Hypersensitivity to Chemotherapy Drugs: A Practical Approach in a Tertiary Care Setting.

Methods and protocols·2026
Same author

Long-term outcome of isolated locoregional breast cancer recurrence: a large retrospective mono-institutional study.

The oncologist·2026
This summary is machine-generated.

Disialoganglioside GD2 is prevalent in aggressive breast cancer (BC) subtypes, including triple-negative and metaplastic variants. This finding highlights GD2

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunohistochemistry

Background:

  • Breast cancer (BC) is a heterogeneous disease with varying prognoses among subtypes.
  • Claudin-low and basal-like BC subtypes exhibit mesenchymal features and poor outcomes.
  • Disialoganglioside GD2, a neuroectodermal antigen, has potential but underexplored roles in BC.

Purpose of the Study:

  • To investigate the expression of Disialoganglioside GD2 in breast cancer (BC) patient specimens.
  • To correlate GD2 expression with clinical-pathological features of BC.
  • To determine the prevalence of GD2 in aggressive BC subtypes.

Main Methods:

  • Analysis of 63 BC patient surgical specimens (2001-2014) without prior neoadjuvant therapy.
  • Immunohistochemistry was used to assess GD2 staining intensity and percentage of positive cells.
Keywords:
BCGD2TNBCdisialogangliosidemetaplastic

Related Experiment Videos

  • Semi-quantitative scoring system and logistic regression analysis were employed.

    • Main Results:

    • GD2 staining was positive in 59% of the evaluated breast cancer (BC) cohort.
    • Significant associations were found between GD2 expression and triple-receptor negative phenotype.
    • Metaplastic carcinoma specimens showed a high prevalence of GD2 positivity.

    Conclusions:

    • Disialoganglioside GD2 is highly prevalent in aggressive breast cancer (BC) subtypes.
    • GD2 expression is linked to triple-negative and metaplastic BC variants.
    • These findings suggest GD2's potential role in aggressive BC biology.